4DMedicalASX:4DX -1.31%64 PS Ratio is 377.50 as of Jun. 30, 2026, which is 116% above its 10-year median of 175.00. GuruFocus rates ASX:4DX with a GF Score™ of 64/100 and a GF Value™ of A$1.44 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 804 Medical Devices & Instruments companies, 4DMedical ranks worse than 98.88% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, 4DMedical's share price is A$4.53.
4DMedical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.01. Hence, 4DMedical's PS Ratio for today is 377.50.
The historical rank and industry rank for 4DMedical's PS Ratio or its related term are showing as below:
ASX:4DX'
s PS Ratio Range Over the Past 10 Years
Min: 8.7 Med: 175 Max: 1585
Current: 377.5
During the past 6 years, 4DMedical's highest PS Ratio was 1585.00. The lowest was 8.70. And the median was 175.00.
ASX:4DX's PS Ratio is ranked worse than 98.88% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs ASX:4DX: 377.50
4DMedical Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of 4DMedical was -20.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 75.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 37.20% per year.
During the past 6 years, 4DMedical's highest 3-Year average Revenue per Share Growth Rate was 108.00% per year. The lowest was -50.00% per year. And the median was 75.40% per year.
Back to Basics: PS Ratio
4DMedical (ASX:4DX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
4DMedical PS Ratio Related Terms
4DMedical PS Ratio Historical Data
* Premium members only.
The historical data trend for 4DMedical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, 4DMedical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4DMedical PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 4DMedical's PS Ratio distribution charts can be found below:
* The bar in red indicates where 4DMedical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
4DMedical's Share Price of today is A$4.53.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 4DMedical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
4DMedical (ASX:4DX) has a PS Ratio of 377.50 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on 4DMedical and its competitors. This is 116% above median its historical median of 175.00. Over the past decade, 4DMedical's PS Ratio has ranged from 8.70 to 1,585.00. According to the industry distribution chart, 4DMedical ranks #795 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 98.9%.
Is 4DMedical's PS Ratio too high?
4DMedical's current PS Ratio of 377.50 is 116% above median its 10-year median of 175.00. Over the past 10 years, this metric has ranged from a low of 8.70 to a high of 1,585.00. The Medical Devices & Instruments industry median PS Ratio is 2.94. 4DMedical's value of 377.50 is 12740.1% above this industry median. Based on the distribution chart, 4DMedical ranks #795 out of 804 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, 4DMedical has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 4DMedical's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, 4DMedical ranks #795 out of 804 companies for PS Ratio. This places 4DMedical in the lower half of its industry. The industry median PS Ratio is 2.94. 4DMedical's value of 377.50 is 12740.1% above this benchmark. Historically, 4DMedical's own PS Ratio has ranged from 8.70 to 1,585.00 over the past decade. While the company's 10-year median is 175.00 vs. the industry median of 2.94, 4DMedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4DMedical's current PS Ratio of 377.50 is 12740.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on 4DMedical and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4DMedical's current PS Ratio is 377.50, which is 116% above median its own 10-year median of 175.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4DMedical stock overvalued right now?
Based on GuruFocus' analysis, 4DMedical (ASX:4DX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$1.44, compared to a current price of A$4.53 — trading 214.6% above its estimated fair value. The current PS Ratio is 377.50, which is 116% above median its 10-year median of 175.00 and 12740.1% above the Medical Devices & Instruments industry median of 2.94. 4DMedical's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For 4DMedical (ASX:4DX), the current PS Ratio is 377.50 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4DMedical (ASX:4DX) Overvalued in 2026?
Based on GuruFocus' analysis, 4DMedical stock appears to be overvalued.
The current stock price of A$4.53 is trading 214.6% above its estimated GF Value™ of A$1.44.
GuruFocus considers 4DMedical to be Significantly Overvalued.
Key valuation signals for ASX:4DX:
PS Ratio: 377.50 (116% above median its 10-year median of 175.00)
GF Value™: A$1.44 vs. price of A$4.53 (214.6% above fair value)
Industry Position: 12740.1% above the Medical Devices & Instruments median (#795 of 804)
No single metric tells the full story. See the ASX:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
64GF Score
Get the complete analysis for ASX:4DX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:4DX has been successfully added to your 
